PEX3 and melanoma: Our data showed that cotargeting PEX3 and UGCG could (a) sensitize RAS-mutant and NF1-mutant melanoma cells to MEKi-induced apoptosis, (b) delay the onset of acquired resistance in vivo, and (c) restore drug sensitivity in resistant/relapsed melanomas.